Novonesis AS

M&A Activity • Jan 31, 2013

The acquisition complements Novozymes' existing business in the pulp & paper,
textile, grain-processing and animal feed industries.

Novozymes acquires Iogen Bio-Products, the industrial enzyme business of
Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370
million) and potential earn-out payments of up to CAD 12.5 million
(approximately DKK 70 million). The deal provides Novozymes with all commercial
rights to Iogen Bio-Products’ existing product portfolio, pipeline, facilities
and know-how. Novozymes acquires all of Iogen Corporation’s industrial enzyme
business. The acquisition does not include the purchase of assets that relate
to Iogen Corporation’s bioenergy process technologies.

Iogen Bio-Products, which entered the industrial enzyme industry in 1991,
produces and sells enzymes for the pulp & paper, textile, grain-processing and
animal feed industries. The company has close to 70 employees and sells more
than 20 products globally.

“Iogen Bio-Products is a good fit for Novozymes,” says Andrew Fordyce, Vice
President of Global Enzyme Sales and Customer Solutions at Novozymes. “We get a
number of products that complement our existing product portfolio and welcome a
talented group of employees who are very good at developing and producing
industrial enzymes.”

Financial impact

The acquisition is expected to have a positive impact on Novozymes’ sales
growth in 2013 of around 0.5 percentage point depending on when the acquisition
is closed. The acquisition is expected to have a slightly negative impact on
EBIT and EBIT margin in 2013, but outlook for EBIT growth and EBIT margin
remains unchanged. The outlook for ROIC for 2013 is being changed from ~20% to
19-20% as a result of the additional capital invested. Novozymes' outlook for
free cash flow excludes acquisitions and remains unchanged for 2013. Outlook
assumes rates for the company’s key currencies remain at the closing rates on
January 18 for the rest of 2013.

Closing of the acquisition is anticipated late February 2013, awaiting
finalization of corporate formalities.

Contact persons: Investor Relations:
Press and media:
René Tronborg (DK) Maarit Pokkinen (DK)
Tel.: +45 3077 2274 Tel.: +45 3077 8682
Paige Donnelly (USA) Martin Riise (DK)
Tel.: +1 919 2184501 Tel.: +45 3077 0738
Thomas Bomhoff (USA),
Tel.: +1 919 6492565
DK Tel.: +45 3077 1226